公开(公告)号：US20240350568A1

公开(公告)日：2024-10-24

申请号：US18221977

申请日：2023-07-14

申请人： LVLH Tech Holdings LLC

发明人： Jiangxin WANG ,  Shiyu XU

IPC分类号： A61K36/05 ,  A61K35/68 ,  A61K36/48 ,  A61K36/725 ,  A61K36/815 ,  A61K36/82 ,  A61K36/896 ,  A61K36/899 ,  A61P25/20 ,  A61P25/24

CPC分类号： A61K36/05 ,  A61K35/68 ,  A61K36/48 ,  A61K36/725 ,  A61K36/815 ,  A61K36/82 ,  A61K36/896 ,  A61K36/899 ,  A61P25/20 ,  A61P25/24

摘要： The present disclosure relates to a natural water-soluble plant compound with antidepressant and sleep-promoting effects, and a preparation method and use thereof. In the present disclosure, the preparation method includes: immersing Fructus lycii, green tea, spina date seed, lily, sugarcane, peanut stem, Euglena, and Chlorella in water, and conducting ultrasonication and first solid-liquid separation to obtain a plant extract; mixing the plant extract with an organic extractant to extract an extracted aqueous phase; removing a solvent of the extracted aqueous phase to obtain a crude extract; dispersing the crude extract into water, and conducting second solid-liquid separation to obtain a purified water extract; and drying the purified water extract to obtain the natural water-soluble plant compound. The natural water-soluble plant compound shows a wide range of neuroactivity, and has an important broad-spectrum improvement effect on alleviating various discomforts caused by the fast-paced and high-stress life of modern people.

公开(公告)号：US20240269218A1

公开(公告)日：2024-08-15

申请号：US17923721

申请日：2022-07-07

申请人： ROMANSIVE CO., LTD.

发明人： Soo Hyun LEE ,  Ju Hui CHOI

IPC分类号： A61K36/725 ,  A61K9/00 ,  A61K31/197 ,  A61K33/06 ,  A61P25/20

CPC分类号： A61K36/725 ,  A61K9/0056 ,  A61K31/197 ,  A61K33/06 ,  A61K36/3486 ,  A61P25/20 ,  A61K2236/19

摘要： The present invention relates to a composition for promoting and improving sleep comprising lactic acid bacteria fermented extract for sanjoin extract as an active ingredient. Sanjoin extract according to the present invention showed an increase in the content of spinosin and an increase in the content of glycine related to sleep promotion and improvement effects through lactic acid bacteria fermentation. In addition, by confirming the excellent sleep promotion and improvement effect by the mixed fermented beverage prepared by further mixing hop extract, L-theanine and magnesium, etc. with the lactic acid bacteria fermented sanjoin extract of the present invention, sleep promotion and It can be usefully used in various health processed foods that can help improve.

公开(公告)号：US20240245650A1

公开(公告)日：2024-07-25

申请号：US18176296

申请日：2023-02-28

申请人： BioXcel Therapeutics, Inc.

发明人： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC分类号： A61K31/4174 ,  A61K9/00 ,  A61K47/38 ,  A61P25/18 ,  A61P25/20

CPC分类号： A61K31/4174 ,  A61K9/006 ,  A61K47/38 ,  A61P25/18 ,  A61P25/20

摘要： Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US12011470B2

公开(公告)日：2024-06-18

申请号：US17711014

申请日：2022-03-31

申请人： Clint Sorensen ,  Melanie Montgomery ,  Matt Smith

发明人： Clint Sorensen ,  Melanie Montgomery ,  Matt Smith

IPC分类号： A61K36/185 ,  A61K9/00 ,  A61K9/107 ,  A61K31/05 ,  A61K31/352 ,  A61P25/20

CPC分类号： A61K36/185 ,  A61K9/0053 ,  A61K9/1075 ,  A61K31/05 ,  A61K31/352 ,  A61P25/20

摘要： This disclosure provides cannabinoid preparations for human consumption that have proven clinical benefits. The preparations are made from full-spectrum hemp oil, which includes a mixture of cannabinoids that work synergistically to achieve the beneficial effects. The hemp oil is micellized, which increases intestinal absorption, resulting in higher potency and a more rapid onset of action. The micellized oil may be combined with micellized cinnamon or clove oil as a flavor enhancer. When consumed daily, the combination of using full spectrum hemp oil with micellization imparts the consumer with an improvement in well-being by several criteria. Benefits include a reduction in inflammatory cytokines, lowering in glucose levels, and weight loss. The micellized cannabinoid preparations of this invention improves sleep quality by extending the period of time spent in deep sleep.

公开(公告)号：US11998529B2

公开(公告)日：2024-06-04

申请号：US18216890

申请日：2023-06-30

申请人： BioXcel Therapeutics, Inc.

发明人： Vasukumar Kakumanu ,  David Christian Hanley ,  Frank Yocca ,  Chetan Dalpatbhai Lathia ,  Lavanya Rajachandran ,  Robert Risinger

IPC分类号： A61K31/4174 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44 ,  A61P25/18 ,  A61P25/20 ,  A61P25/36

CPC分类号： A61K31/4174 ,  A61K9/006 ,  A61K9/06 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/7007 ,  A61K9/7015 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44 ,  A61P25/18 ,  A61P25/20 ,  A61P25/36

摘要： Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US20240173299A1

公开(公告)日：2024-05-30

申请号：US18430003

申请日：2024-02-01

申请人： BioXcel Therapeutics, Inc.

发明人： Vasukumar KAKUMANU ,  David Christian HANLEY ,  Frank YOCCA ,  Chetan Dalpatbhai LATHIA ,  Lavanya RAJACHANDRAN ,  Robert RISINGER

IPC分类号： A61K31/4174 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44 ,  A61P25/18 ,  A61P25/20 ,  A61P25/36

CPC分类号： A61K31/4174 ,  A61K9/006 ,  A61K9/06 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/7007 ,  A61K9/7015 ,  A61K47/10 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K47/44 ,  A61P25/18 ,  A61P25/20 ,  A61P25/36

摘要： Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

公开(公告)号：US11993628B2

公开(公告)日：2024-05-28

申请号：US17242913

申请日：2021-04-28

申请人： Sage Therapeutics, Inc.

发明人： Albert Jean Robichaud ,  Gabriel Martinez Botella ,  Boyd L. Harrison ,  Francesco G. Salituro ,  Andrew Griffin ,  Maria Jesus Blanco-Pillado

IPC分类号： A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/20 ,  C07J1/00 ,  C07J7/00 ,  C07J41/00 ,  C07J43/00

CPC分类号： C07J43/003 ,  A61P25/00 ,  C07J1/0029 ,  C07J7/002 ,  C07J7/003 ,  C07J7/006 ,  C07J41/005 ,  C07J41/0094

摘要： Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.

公开(公告)号：US20240132535A1

公开(公告)日：2024-04-25

申请号：US18216057

申请日：2023-06-29

申请人： Sage Therapeutics, Inc.

发明人： Francesco G. Salituro ,  Albert Jean Robichaud ,  Gabriel Martinez Botella ,  Boyd L. Harrison

IPC分类号： C07J9/00 ,  A61P3/00 ,  A61P23/00 ,  A61P25/20 ,  C07J17/00

CPC分类号： C07J9/00 ,  A61P3/00 ,  A61P23/00 ,  A61P25/20 ,  C07J17/00 ,  C07J31/006

摘要： Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

公开(公告)号：US20240075035A1

公开(公告)日：2024-03-07

申请号：US18271716

申请日：2022-01-12

申请人： APNIMED, INC. (DELAWARE)

发明人： Ronald FARKAS ,  Luigi TARANTO-MONTEMURRO ,  Lawrence G MILLER

IPC分类号： A61K31/513 ,  A61K31/138 ,  A61K31/216 ,  A61P11/04 ,  A61P25/20

CPC分类号： A61K31/513 ,  A61K31/138 ,  A61K31/216 ,  A61P11/04 ,  A61P25/20

摘要： Pharmaceutical compositions comprising Lemborexant or a pharmaceutically acceptable salt thereof and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering Lemborexant or a pharmaceutically acceptable salt thereof and an NRI are described herein. In some embodiments, the NRI is atomoxetine or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions further comprise a muscarinic receptor antagonist (MRA). In some embodiments, the methods of treating Sleep Apnea further comprise administering an MRA. In some embodiments, the MRA is oxybutynin or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11918557B2

公开(公告)日：2024-03-05

申请号：US18183655

申请日：2023-03-14

申请人： Vanda Pharmaceuticals Inc.

发明人： Marlene Michelle Dressman ,  Louis William Licamele ,  Mihael H. Polymeropoulos

IPC分类号： A61K31/343 ,  A61K9/00 ,  A61K31/00 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  A61K45/06 ,  A61P25/20 ,  G01N30/72 ,  G01N33/68 ,  G01N33/74 ,  G16H50/20

CPC分类号： A61K31/343 ,  A61K9/0053 ,  A61K9/006 ,  A61K31/00 ,  A61K31/15 ,  A61K31/277 ,  A61K31/496 ,  A61K45/06 ,  A61P25/20 ,  G01N30/7233 ,  G01N33/6893 ,  G01N33/74 ,  G16H50/20 ,  G01N2800/2864

摘要： Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.